Kathleen Mullane DO Pharm. D.

HIV/AIDS Medicine, Transplant/Immunocompromised States

Medical Director, PPD; a division of Thermo-Fischer Professor of Medicine; University of Chicago Department of Medicine; Section of Infectious Diseases

Join to view full profile

374 Bartram RdM/C 5065Riverside, IL 60546
Phone+1 708-227-5299

Dr. Mullane is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mullane's full profile Already have an account?

Summary

Dr. Kathleen Mullane is an Infectious Disease specialist in Chicago, IL. She is a Medical Director for PPD, a division of Thermo-Fischer in the department of Pharmacovigilance and is affiliated with University of Chicago Medical Center. She received her medical degree from Midwestern University / Chicago College of Osteopathic Medicine and has been in practice 28 years.
Clinically, she specializes in transplant /immunocompromised infectious disease states and is experienced in general infectious diseases, HIV, COVID-19, C. difficile colitis, healthcare outcomes research. In clinical trials research she has participated in trials involving vaccines, antifungal agents, antiviral agents and antibacterial agents.

Education & Training

University of ChicagoFellowship, Infectious Disease, 1992 - 1994
University of Illinois College of Medicine at ChicagoFellowship, Infectious Disease, 1992 - 1994
Rush University Medical CenterResidency, Internal Medicine, 1989 - 1992
Chicago College of Osteopathic Medicine at Midwestern UniversityClass of 1989
University of Illinois College of Medicine at ChicagoPharm D, Clinical Pharmacy, 1982 - 1983

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

IL State License 1992 - 2029

Awards, Honors, & Recognition

Top Doctor Chicago Magazine, 2012, 2020-2023
Top Doctor US News and World Report, 2012-2023
Top Doctor Castle Connelly / US News and World Report, 2012-2023

Clinical Trials

DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP)
TERMINATED
PHASE3
A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients
COMPLETED
PHASE3
Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus Infection
COMPLETED
PHASE3

Publications & Presentations

PubMed

2 citations
Expect the unexpected: endocarditis caused by Legionella feeleii.
Angelica Moran, Dennise E Otero Espinal, Megan Parilla, Kathleen G Beavis, Kathleen M Mullane
Laboratory Medicine. 2024-11-04
11 citations
MSG-15: Super-Bioavailability Itraconazole Versus Conventional Itraconazole in the Treatment of Endemic Mycoses-A Multicenter, Open-Label, Randomized Comparative Trial.
Andrej Spec, George R Thompson, Marisa H Miceli, Justin Hayes, Laurie Proia
Open Forum Infectious Diseases. 2024-03-01
11 citations
A Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vacci...
Marissa Wilck, Oliver A Cornely, Catherine Cordonnier, Juan Diego Velez, Per Ljungman
Clinical Infectious Diseases. 2023-10-13

Journal Articles

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19
Robert L Gottlieb, Gerard J Criner, Onyema Ogbuagu, Kathleen M Mullane, Anuj Gaggar, Diana M Brainard, Gregory Huhn, JAMA
Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials
Roy F Chemaly, Kathleen M Mullane, Robin Avery, Raymund R Razonable, Clinical Infectious Diseases
Misdiagnosis of Bordetella Bronchiseptica Respiratory Infection as Bordetella Pertussis by Multiplex Molecular Assay
Vera Tesic, Kathleen Mullane, Kathleen G Beavis, Jennifer Pisano, Moira C McNulty, Jennifer L Steinbeck, David Pitrak, Clinical Infectious Diseases

Lectures

New Insights into the Diagnosis and Treatment of CDI.
Park Ridge, IL - 9/17/2013
New Treatments in the Management of CDI.
Lansing, MI - 8/7/2013
C-Diff Infection: Changing Trends & New Treatments for the Enemy Within.
Englewood, CO - 4/27/2013

Other

Prevention, Diagnosis and Management of Opportunistic Infections in Individuals Living with Chronic Graft versus Host Disease.
Mullane KM, Living with Chronic GVHD; An Educational Symposium for Patients, Families and Healthcare Professiona
http://bmtinfonet.org/
10/30/2010
The 2007 Process of Care (TM) Management of Invasive Fungal Infections: Spectrum of Antifungal Therapies.
Mullane KM, University of Medicine of New Jersey and Dentistry; Center for Continuing and Outreach Education and
12/1/2007
Efficacy and Safety of Echinocandin Prophylaxis against Invasive Fungal Infection during Stem Cell Transplantation.
Mullane KM, University of Medicine of New Jersey and Dentistry Center for Continuing and Outreach Education and
4/1/2005

Authored Content

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020

Press Mentions

mRNA Vaccines Get Ready for Their Next Act: Fighting CancerSeptember 21st, 2021
You're More Likely to Have This Symptom with the Delta Variant, Doctors SayAugust 27th, 2021
New Study Shows One Dose of COVID-19 Is Not Enough to Protect Against Delta VariantJuly 8th, 2021